BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Gemayel is also chairman of Enterome Bioscience S.A. (Paris, France), Orphazyme A/S (Copenhagen, Denmark) and OxThera AB...
BioCentury | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

...Kubik as CBO. He was CBO of i2 Pharmaceuticals Inc. (Boulder, Colo.). Rare disease company OxThera AB...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB...
BioCentury | Jul 15, 2017
Company News

Management tracks

...Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB...
BioCentury | Dec 2, 2016
Financial News

OxThera completes venture financing

...investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden Alicia Parker OxThera AB...
BioCentury | Dec 1, 2016
Financial News

OxThera raises EUR 32M

...Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet. OxThera...
...short bowel syndrome (SBS). It is a capsule formulation of lyophilized live Oxalobacter formigenes . Chris Lieu Oxabact OxThera AB...
BioCentury | Sep 29, 2014
Clinical News

Oxabact regulatory update

...The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome...
...U.S. to treat primary hyperoxaluria, for which the compound is in a Phase II trial. OxThera AB...
BioCentury | Apr 21, 2014
Financial News

OxThera completes venture financing

OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Date completed: 4/16/14 Type: Venture financing Raised: SEK70 million ($10.7 million) Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors WIR Staff...
BioCentury | Feb 17, 2014
Company News

OxThera board of directors update

OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Appointed: Georges Gemayel as chairman WIR Staff...
BioCentury | Jan 20, 2014
Clinical News

Oxabact: Phase I/II started

...primary hyperoxaluria. Oxabact has Orphan Drug designation for the indication in the EU and U.S. OxThera AB...
Items per page:
1 - 10 of 19
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Gemayel is also chairman of Enterome Bioscience S.A. (Paris, France), Orphazyme A/S (Copenhagen, Denmark) and OxThera AB...
BioCentury | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

...Kubik as CBO. He was CBO of i2 Pharmaceuticals Inc. (Boulder, Colo.). Rare disease company OxThera AB...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

...innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB...
BioCentury | Jul 15, 2017
Company News

Management tracks

...Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB...
BioCentury | Dec 2, 2016
Financial News

OxThera completes venture financing

...investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden Alicia Parker OxThera AB...
BioCentury | Dec 1, 2016
Financial News

OxThera raises EUR 32M

...Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet. OxThera...
...short bowel syndrome (SBS). It is a capsule formulation of lyophilized live Oxalobacter formigenes . Chris Lieu Oxabact OxThera AB...
BioCentury | Sep 29, 2014
Clinical News

Oxabact regulatory update

...The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome...
...U.S. to treat primary hyperoxaluria, for which the compound is in a Phase II trial. OxThera AB...
BioCentury | Apr 21, 2014
Financial News

OxThera completes venture financing

OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Date completed: 4/16/14 Type: Venture financing Raised: SEK70 million ($10.7 million) Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors WIR Staff...
BioCentury | Feb 17, 2014
Company News

OxThera board of directors update

OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Appointed: Georges Gemayel as chairman WIR Staff...
BioCentury | Jan 20, 2014
Clinical News

Oxabact: Phase I/II started

...primary hyperoxaluria. Oxabact has Orphan Drug designation for the indication in the EU and U.S. OxThera AB...
Items per page:
1 - 10 of 19